HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Javor, E. D. Articles by Gorden, P. Search for Related Content PubMed PubMed Citation Articles by Javor, E. D. Articles by Gorden, P. Social Bookmarking                What's this?

Long-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy

¹ Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
² Amgen, Thousand Oaks, California

Ectopic fat accumulation has been implicated as a contributing factor in the abnormal metabolic state of obesity. One human model of ectopic fat deposition is generalized lipodystrophy. Generalized lipodystrophy is a rare disorder characterized by a profound deficiency of adipose tissue with resultant loss of triglyceride storage capacity and reduced adipokines, including leptin. Subjects with generalized lipodystrophy and reduced leptin levels often have an increased appetite leading to hyperphagia. Excess fuel consumption, coupled with a lack of adipose tissue, contributes to the significant ectopic triglyceride accumulation in the muscle and liver seen in these subjects. This ectopic fat, along with the deficiency in leptin signaling and perhaps other adipokines, likely contributes to insulin resistance, diabetes, and hepatic steatosis. We report here the long-term effects of leptin replacement in a cohort of these subjects. Fifteen patients with generalized lipodystrophy were treated with twice-daily recombinant methionyl human leptin (r-metHuLeptin) for 12 months. We evaluated metabolic parameters at baseline and every 4 months. Antidiabetes medications were decreased or discontinued as necessary. Reductions were seen in serum fasting glucose (from 205 ± 19 to 126 ± 11 mg/dl; P < 0.001), HbA_1c (from 9 ± 0.4 to 7.1 ± 0.5%; P < 0.001), triglycerides (from 1,380 ± 500 to 516 ± 236 mg/dl; P < 0.001), LDL (from 139 ± 16 to 85 ± 7 mg/dl; P < 0.01), and total cholesterol (from 284 ± 40 to 167 ± 21 mg/dl; P < 0.01). HDL was unchanged (from 31 ± 3 to 29 ± 2 mg/dl; P = 0.9). Liver volumes were significantly reduced (from 3,663 ± 326 to 2,190 ± 159 cm³; P < 0.001), representing loss of steatosis. Decreases were seen in total body weight (from 61.8 ± 3.6 to 57.4 ± 3.4 kg; P = 0.02) and resting energy expenditure (from 1,929 ± 86 to 1,611 ± 101 kcal/24 h; P < 0.001). R-metHuLeptin led to significant and sustained improvements in glycemia, dyslipidemia, and hepatic steatosis. Leptin represents the first novel, effective, long-term treatment for severe forms of lipodystrophy.

Abbreviations: AGL, acquired generalized lipodystrophy; CGL, congenital generalized lipodystrophy; NAFLD, nonalcoholic fatty liver disease; PPAR, peroxisome proliferator-activated receptor; REE resting energy expenditure; r-metHuLeptin, recombinant methionyl human leptin

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. G. Bermudez-Humaran, S. Nouaille, V. Zilberfarb, G. Corthier, A. Gruss, P. Langella, and T. Issad Effects of Intranasal Administration of a Leptin-Secreting Lactococcus lactis Recombinant on Food Intake, Body Weight, and Immune Response of Mice Appl. Envir. Microbiol., August 15, 2007; 73(16): 5300 - 5307. [Abstract] [Full Text] [PDF]

				A. McDonald, R. M Williams, F. M Regan, R. K Semple, and D. B Dunger IGF-I treatment of insulin resistance Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S51 - S56. [Abstract] [Full Text] [PDF]

				J. Beltrand, M. Beregszaszi, D. Chevenne, G. Sebag, M. De Kerdanet, F. Huet, M. Polak, N. Tubiana-Rufi, D. Lacombe, A. M. De Paoli, et al. Metabolic Correction Induced by Leptin Replacement Treatment in Young Children With Berardinelli-Seip Congenital Lipoatrophy Pediatrics, August 1, 2007; 120(2): e291 - e296. [Abstract] [Full Text] [PDF]

				J. J. Dube, B. A. Bhatt, N. Dedousis, A. Bonen, and R. M. O'Doherty Leptin, skeletal muscle lipids, and lipid-induced insulin resistance Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R642 - R650. [Abstract] [Full Text] [PDF]

				K. Ebihara, T. Kusakabe, M. Hirata, H. Masuzaki, F. Miyanaga, N. Kobayashi, T. Tanaka, H. Chusho, T. Miyazawa, T. Hayashi, et al. Efficacy and Safety of Leptin-Replacement Therapy and Possible Mechanisms of Leptin Actions in Patients with Generalized Lipodystrophy J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 532 - 541. [Abstract] [Full Text] [PDF]

				P. F. Pilch and N. Bergenhem Pharmacological Targeting of Adipocytes/Fat Metabolism for Treatment of Obesity and Diabetes Mol. Pharmacol., September 1, 2006; 70(3): 779 - 785. [Abstract] [Full Text] [PDF]

				D. J. Jenkins, A. R Josse, R. Labelle, A. Marchie, L. S. Augustin, and C. W. Kendall Nonalcoholic fatty liver, nonalcoholic steatohepatitis, ectopic fat, and the glycemic index Am. J. Clinical Nutrition, July 1, 2006; 84(1): 3 - 4. [Full Text] [PDF]

				C. Musso, E. Javor, E. Cochran, J. E Balow, and P. Gorden Spectrum of Renal Diseases Associated with Extreme Forms of Insulin Resistance Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 616 - 622. [Abstract] [Full Text] [PDF]

				H. Poirier, J. S. Shapiro, R. J. Kim, and M. A. Lazar Nutritional Supplementation With trans-10, cis-12-Conjugated Linoleic Acid Induces Inflammation of White Adipose Tissue Diabetes, June 1, 2006; 55(6): 1634 - 1641. [Abstract] [Full Text] [PDF]

				A. M. Hennige, N. Stefan, K. Kapp, R. Lehmann, C. Weigert, A. Beck, K. Moeschel, J. Mushack, E. Schleicher, and H.-U. Haring Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1 FASEB J, June 1, 2006; 20(8): 1206 - 1208. [Abstract] [Full Text] [PDF]

				E. A. Oral, E. D. Javor, L. Ding, G. Uzel, E. K. Cochran, J. R. Young, A. M. DePaoli, S. M. Holland, and P. Gorden Leptin Replacement Therapy Modulates Circulating Lymphocyte Subsets and Cytokine Responsiveness in Severe Lipodystrophy J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 621 - 628. [Abstract] [Full Text] [PDF]